Emergent strategy in management of inflammatory bowel disease: A narrowed in on novel drugs

Inflammatory bowel disease is looming large on the modern society which has raised the brows of the medical scientists in both the developed and developing countries. According to American Gastrological Society (AGS) IBD is defined acute or chronic idiopathic ulceroinflammatory condition of the bowel which may or may not have transmural stretch. IBD encompasses two pivotal kinds of pathological condition Ulcerative colitis (UC) and Crohn's disease (CD). Epidemiologically UC has a greater prevalence in the global prospective. So we decided to zero in on UC in our work ahead. Pivotal contours may be featured as toxic megacolon, pseudopolyps and backwash ileitis. The featured encountered in the clinical course of the disease are multiferrous spanning from rectal bleeding, abdominal pain, weight loss and malasei. Coming to the option available for management they include both non pharmacological approach and pharmacological approach. Under the nonpharmacological approach life style changes like monitored dieting, exercise may plays a pivotal role and psychological intervention also deployed to control the functional aspects of the disease. On the other hand Salfasalazine and Mesalamine are still considered as a corner stone of the therapy as per as pharmacological approach.